Clinical Trial Update: Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating protein C levels in severe sepsis patients treated with drotrecogin alfa (activated) has completed, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Drotrecogin alfa (activated) (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Severe Sepsis | Phase 2 | Status: COMPLETED | Results posted: 2010-12-16